Chemotherapy and targeted therapies for unresectable malignant mesothelioma

Lung Cancer

Volumn 73, Issue 3, 2011, Pages 256-263

  Kelly, Ronan Joseph ^a   Sharon, Elad ^a   Hassan, Raffit ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Immunotherapy; Mesothelioma; MORAb 009; SS1P; Targeted therapy

Indexed keywords

AMATUXIMAB; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CANCER VACCINE; CARBOPLATIN; CBP 501; CISPLATIN; CRS 207; ERLOTINIB; EVEROLIMUS; FRESOLIMUMAB; GANCICLOVIR; GEFITINIB; GEMCITABINE; MITOMYCIN; NAVELBINE; OXALIPLATIN; PEMETREXED; PLACEBO; RALTITREXED; SORAFENIB; SS 1P; SUNITINIB; THALIDOMIDE; UNCLASSIFIED DRUG; VATALANIB; VINBLASTINE; VORINOSTAT;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTINUOUS INFUSION; DRUG DOSE ESCALATION; DRUG MEGADOSE; HUMAN; INOPERABLE CANCER; MALIGNANT MESOTHELIOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; DRUG THERAPY; FOLIC ACID ANTAGONISTS; GENE THERAPY; GLUTAMATES; GUANINE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; IMMUNOTHERAPY; MESOTHELIOMA; MOLECULAR TARGETED THERAPY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VINBLASTINE;

EID: 79960890437     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.04.014     Document Type: Review

References (81)

1. Wagner J.C., Sleggs C.A., Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960, 17:260-271.
2. Hodgson J.T., McElvenny D.M., Darnton A.J., Price M.J., Peto J., et al. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005, 92:587-593.
3. O'Byrne K.J., Edwards J.G., Waller D.A. Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma. Lung Cancer 2004, 45(Suppl 1):S45-S48.
4. Herndon J.E., Green M.R., Chahinian A.P., Corson J.M., Suzuki Y., Vogelzang N.J., et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998, 113:723-731.
5. Wong L., Zhou J., Anderson D., Kratzke R.A. Inactivation of p16INK4a expression in malignant mesothelioma by methylation. Lung Cancer 2002, 38:131-136.
6. Yang C.T., You L., Yeh C.C., Chang J.W., Zhang F., McCormick F., et al. Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells. J Natl Cancer Inst 2000, 92:636-641.
7. Schipper H., Papp T., Johnen G., Pemsel H., Bastrop R., Muller K.M., et al. Mutational analysis of the nf2 tumour suppressor gene in three subtypes of primary human malignant mesotheliomas. Int J Oncol 2003, 22:1009-1017.
8. Berghmans T., Paesmans M., Lalami Y., Louviaux I., Luce S., Mascaux C., et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002, 38:111-121.
9. Ellis P., Davies A.M., Evans W.K., Haynes A.E., Lloyd N.S, et al. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol 2006, 1:591-601.
10. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644.
11. van Meerbeeck J.P., Gaafar R., Manegold C., Van Klaveren R.J., Van Marck E.A., Vincent M., et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005, 23:6881-6889.
12. Schultz R.M., Chen V.J., Bewley J.R., Roberts E.F., Shih C., Dempsey J.A., et al. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol 1999, 26:68-73.
13. Mendelsohn L.G., Shih C., Chen V.J., Habeck L.L., Gates S.B., Shackelford K.A., et al. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol 1999, 26:42-47.
14. Moran R.G. Roles of folylpoly-gamma-glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: an overview. Semin Oncol 1999, 26(2 Suppl 6):24-32.
15. Shih C., Chen V.J., Gossett L.S., Gates S.B., MacKellar W.C., Habeck L.L., et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997, 57:1116-1123.
16. Santoro A., O'Brien M.E., Stahel R.A., Nackaerts K., Baas P., Karthaus M., et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 2008, 3:756-763.
17. Hughes A., Calvert P., Azzabi A., Plummer R., Johnson R., Rusthoven J., et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 2002, 20:3533-3544.
18. Ceresoli G.L., Zucali P.A., Favaretto A.G., Grossi F., Bidoli P., Del Conte G., et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006, 24:1443-1448.
19. Ceresoli G.L., Zucali P.A., De Vincenzo F., Gianoncelli L., Simonelli M., Lorenzi E., et al. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer 2011, 72:73-77.
20. Righi L., Papotti M.G., Ceppi P., Bille A., Bacillo E., Molinaro L., et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol 2010, 28:1534-1539.
21. Janne P.A. Chemotherapy for malignant pleural mesothelioma. Clin Lung Cancer 2003, 5:98-106.
22. Byrne M.J., Davidson J.A., Musk A.W., Dewar J., van Hazel G., Buck M., et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999, 17:25-30.
23. Castagneto B., Zai S., Dongiovanni D., Muzio A., Bretti S., Numico G., et al. Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol 2005, 28:223-226.
24. Kalmadi S.R., Rankin C., Kraut M.J., Jacobs A.D., Petrylak D.P., Adelstein D.J, et al. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer 2008, 60:259-263.
25. Nowak A.K., Byrne M.J., Williamson R., Ryan G., Segal A., Fielding D., et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002, 87:491-496.
26. van Haarst J.M., Baas P., Manegold C., Schouwink J.H., Burgers J.A., de Bruin H.G., et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 2002, 86:342-345.
27. Scagliotti G.V., Shin D.M., Kindler H.L., Vasconcelles M.J., Keppler U., Manegold C., et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003, 21:1556-1561.
28. Adjei A.A., Erlichman C., Sloan J.A., Reid J.M., Pitot H.C., Goldberg R.M., et al. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 2000, 18:1748-1757.
29. Giovannetti E., Mey V., Nannizzi S., Pasqualetti G., Marini L., Del Tacca M., et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 2005, 68:110-118.
30. Ma C.X., Nair S., Thomas S., Mandrekar S.J., Nikcevich D.A., Rowland K.M., et al. Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 2005, 23:5929-5937.
31. Janne P.A., Simon G.R., Langer C.J., Taub R.N., Dowlati A., Fidias P., et al. Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma. J Clin Oncol 2008, 26:1465-1471.
32. Steele J.P., Shamash J., Evans M.T., Gower N.H., Tischkowitz M.D., Rudd R.M., et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000, 18:3912-3917.
33. Sorensen J.B., Frank H., Palshof T. Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br J Cancer 2008, 99(1):44-50.
34. Stebbing J., Powles T., McPherson K., Shamash J., Wells P., Sheaff M.T., et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 2009, 63:94-97.
35. Zucali P.A., Ceresoli G.L., Garassino I., De Vincenzo F., Cavina R., Campagnoli E., et al. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer 2008, 112:1555-1561.
36. Muers M.F., Stephens R.J., Fisher P., Darlison L., Higgs C.M., Lowry E., et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008, 371:1685-1694.
37. Mossman B.T., Gruenert D.C. SV40, growth factors, and mesothelioma: another piece of the puzzle. Am J Respir Cell Mol Biol 2002, 26(2):167-170.
38. Ramos-Nino M.E., Testa J.R., Altomare D.A., Pass H.I., Carbone M., Bocchetta M., et al. Cellular and molecular parameters of mesothelioma. J Cell Biochem 2006, 98:723-734.
39. Edwards J.G., Swinson D.E., Jones J.L., Waller D.A., O'Byrne K.J. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 2006, 54:399-407.
40. Govindan R., Kratzke R.A., Herndon J.E., 2nd G.A., Niehans R., Vollmer D., et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 2005, 11:2300-2304.
41. Lee C.W., Anderson H., Martins H., Rao S.C., Sauciuc D., Laurie S.A., et al. A phase II trial of gefitinib in patients with malignant pleural mesothelioma (MPM). J Clin Oncol (Meeting Abstracts) 2008, 26:14614.
42. Garland L.L., Rankin C., Gandara D.R., Rivkin S.E., Scott K.M., Nagle R.B., et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 2007, 25:2406-2413.
43. Jackman D.M., Kindler H.L., Yeap B.Y., Fidias P., Salgia R., Lucca J., et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 2008, 113:808-814.
44. Velcheti V., Kasai Y., Viswanathan A.K., Ritter J., Govindan R. Absence of mutations in the epidermal growth factor receptor (EGFR) kinase domain in patients with mesothelioma. J Thorac Oncol 2009, 4:559.
45. Karrison T., Kindler H.L., Gandara D.R., Lu C., Guterz T.L., Nichols K., et al. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM). J Clin Oncol (Meeting Abstracts) 2007, 25:7526.
46. Zalcman G., Margery J., Scherpereel A., Astoul P., Monnet I., Milleron B.J., et al. IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma. J Clin Oncol (ASCO Meeting Abstracts) 2010, 28:7020.
47. Dubey S., Janne P.A., Krug L., Pang H., Wang X., Heinze R., et al. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol 2010, 5:1655-1661.
48. Dowell J.E., Kindler H.L. Antiangiogenic therapies for mesothelioma. Hematol Oncol Clin North Am 2005, 19:1137-1145. viii.
49. Jahan T.M., Gu L., Wang X., Kratzke R.A., Dudek A.Z., Green M.R., et al. Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): a phase II study by the Cancer and Leukemia Group B (CALGB 30107). J Clin Oncol (Meeting Abstracts) 2006, 24:7081.
50. Nowak A.K., Millward M., Francis R.J., Hasani A., van der Schaaf A.A., Seguard T., et al. Final results of a phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM). J Clin Oncol (ASCO Meeting Abstracts) 2010, 28:7036.
51. Baas P., Boogerd W., Dalesio O., Haringhuizen A., Custers F., van Zandwijk N., et al. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 2005, 48:291-296.
52. Gordon G.J., Mani M., Maulik G., Mukhopadhyay L., Yeap B.Y., Kindler H.L., et al. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2008, 61:549-558.
53. Sartore-Bianchi A., Gasparri F., Galvani A., Nici L., Darnowski J.W., Barbone D., et al. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res 2007, 13:5942-5951.
54. Marks P.A., Richon V.M., Miller T., Kelly W.K. Histone deacetylase inhibitors. Adv Cancer Res 2004, 91:137-168.
55. Kouzarides T. Histone methylation in transcriptional control. Curr Opin Genet Dev 2002, 12(2):198-209.
56. Freiman R.N., Tjian R. Regulating the regulators: lysine modifications make their mark. Cell 2003, 112(1):11-17.
57. Cao X.X., Mohuiddin I., Ece F., McConkey D.J., Smythe W.R. Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am J Respir Cell Mol Biol 2001, 25:562-568.
58. Krug L.M., Curley T., Schwartz L., Richardson S., Marks P., Chiao J., et al. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 2006, 7:257-261.
59. Dudek A., Pang H., Kratzke R.A., Otterson G.A., Vokes E.E., Kindler H.L., et al. CALGB 30601: a phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma (MM). J Clin Oncol (ASCO Meeting Abstracts) 2010, 28:7037.
60. Mathy A., Baas P., Dalesio O., van Zandwijk N. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 2005, 50:83-86.
61. Porta C., Mutti L., Tassi G. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2007, 59(1):149-150.
62. Ali Y., Lin Y., Gharibo M.M., Gounder M.K., Stein M.N., Lagattuta T.F., et al. Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors. Clin Cancer Res 2007, 13:5876-5882.
63. Bertino P., Piccardi F., Porta C., Favoni R., Cilli M., Mutti L., et al. Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts. Clin Cancer Res 2008, 14:541-548.
64. Sha S.K., Sato T., Kobayashi H., Ishigaki M., Yamamoto S., Sato H., et al. Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint. Mol Cancer Ther 2007, 6:147-153.
65. Ordonez N.G. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003, 16(3):192-197.
66. Argani P., Iacobuzio-Donahue C., Ryu B., Rosty C., Goggins M., Wilentz R.E., et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001, 7:3862-3868.
67. Hassan R., Kreitman R.J., Pastan I., Willingham M.C., et al. Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol 2005, 13:243-247.
68. Ordonez N.G. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003, 27(11):1418-1428.
69. Chang K., Pai L.H., Pass H., Pogrebniak H.W., Tsao M.S., Pastan I., et al. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol 1992, 16:259-268.
70. Rump A., Morikawa Y., Tanaka M., Minami S., Umesaki N., Takeuchi M., et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 2004, 279:9190-9198.
71. Miller J.R., Hocking A.M., Brown J.D., Moon R.T. Mechanism and function of signal transduction by the Wnt/beta-catenin and Wnt/Ca2+ pathways. Oncogene 1999, 18:7860-7872.
72. Zhang Y., Xiang L., Hassan R., Paik C.H., Carrasquillo J.A., Jang B.S., et al. Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. Clin Cancer Res 2006, 12:4695-4701.
73. Hassan R., Ebel W., Routhier E.L., Patel R., Kline J.B., Zhang J., et al. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun 2007, 7:20.
74. Thomas A.M., Santarsiero L.M., Lutz E.R., Armstrong T.D., Chen Y.C., Huang L.Q., et al. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 2004, 200:297-306.
75. Tumor Immunology: Basic and Clinical Advances in conjunction with the Cancer Immunology Working Group of the AACR. Miami Beach, FL, November 30-December 3, 2010 [Abstract, A.C.].
76. Molnar-Kimber K.L., Sterman D.H., Chang M., Kang E.H., ElBash M., Lanuti M., et al. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther 1998, 9:2121-2133.
77. Sterman D.H., Kaiser L.R., Albelda S.M. Gene therapy for malignant pleural mesothelioma. Hematol Oncol Clin North Am 1998, 12(3):553-568.
78. Sterman D.H., Treat J., Litzky L.A., Amin K.M., Coonrod L., Molnar-Kimber K., et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998, 9:1083-1092.
79. Sterman D.H., Recio A., Vachani A., Sun J., Cheung L., DeLong P., et al. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res 2005, 11:7444-7453.
80. Sterman D.H., Recio A., Carroll R.G., Gillespie C.T., Haas A., Vachani A., et al. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res 2007, 13(15 Pt 1):4456-4466.
81. Sterman D.H., Recio A., Haas A.R., Vachani A., Katz S.I., Gillespie C.T., et al. A Phase I trial of repeated Intrapleural Adenoviral-mediated Interferon-beta Gene Transfer for Mesothelioma and Metastatic Pleural Effusions. Mol Ther 2010, 18(4):852-860.